BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 20889528)

  • 1. Predicting local control of choroidal melanomas following ¹⁰⁶Ru plaque brachytherapy.
    Papageorgiou KI; Cohen VM; Bunce C; Kinsella M; Hungerford JL
    Br J Ophthalmol; 2011 Feb; 95(2):166-70. PubMed ID: 20889528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays).
    Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD
    Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local tumor control after 106Ru brachytherapy of choroidal melanoma.
    Damato B; Patel I; Campbell IR; Mayles HM; Errington RD
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):385-91. PubMed ID: 15913907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma.
    Wilson MW; Hungerford JL
    Ophthalmology; 1999 Aug; 106(8):1579-87. PubMed ID: 10442907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irido-cilio-choroidal melanoma in a 5-year-old boy treated by Ru-106 brachytherapy.
    Pe'er J; Averbukh E; Frenkel S
    Clin Exp Ophthalmol; 2009 Sep; 37(7):742-3. PubMed ID: 19788674
    [No Abstract]   [Full Text] [Related]  

  • 6. Tumour control probability after Ruthenium-106 brachytherapy for choroidal melanomas.
    Espensen CA; Appelt AL; Fog LS; Thariat J; Gothelf AB; Aznar MC; Kiilgaard JF
    Acta Oncol; 2020 Aug; 59(8):918-925. PubMed ID: 32412331
    [No Abstract]   [Full Text] [Related]  

  • 7. [Evaluation of 100 melanomas of the choroid and ciliary body treated by application of ruthenium (RU 106 Rh 106)].
    Grange JD; Gerard JP; Ragab M; Quintero P; Delaroche G; Jean-Louis B; Sentenac I; Fontaniere B; Bievelez B
    Bull Soc Ophtalmol Fr; 1989 May; 89(5):679-82. PubMed ID: 2590984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 125I plaque brachytherapy for anterior uveal melanomas.
    Lumbroso-Le Rouic L; Charif Chefchaouni M; Levy C; Plancher C; Dendale R; Asselain B; Solignac S; Mazal A; Desjardins L
    Eye (Lond); 2004 Sep; 18(9):911-6. PubMed ID: 15002010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of eye-conserving treatment with Ruthenium(106) brachytherapy for choroidal melanoma.
    Verschueren KM; Creutzberg CL; Schalij-Delfos NE; Ketelaars M; Klijsen FL; Haeseker BI; Ligtenberg SM; Keunen JE; Marijnen CA
    Radiother Oncol; 2010 Jun; 95(3):332-8. PubMed ID: 20416963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.
    Browne AW; Dandapani SV; Jennelle R; Stevanovic M; Lee TC; Murphree AL; Kampp TD; Astrahan MA; Kim JW; Berry JL
    Brachytherapy; 2015; 14(5):718-25. PubMed ID: 26073224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study.
    Pe'er J; Stefani FH; Seregard S; Kivela T; Lommatzsch P; Prause JU; Sobottka B; Damato B; Chowers I
    Br J Ophthalmol; 2001 Oct; 85(10):1208-12. PubMed ID: 11567966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visual acuity after Ruthenium(106) brachytherapy of choroidal melanomas.
    Damato B; Patel I; Campbell IR; Mayles HM; Errington RD
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):392-400. PubMed ID: 15990248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [High-dose 106Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinico-pathologic study].
    Heindl LM; Lotter M; Strnad V; Sauer R; Naumann GO; Knorr HL
    Ophthalmologe; 2007 Feb; 104(2):149-57. PubMed ID: 17123048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
    Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
    Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor control, eye preservation, and visual outcomes of ruthenium plaque brachytherapy for choroidal melanoma.
    Marconi DG; de Castro DG; Rebouças LM; Bernardes Gil GO; Fogaroli RC; Conte Maia MA; Gobo Silva ML; Assis Pellizzon AC; Motono Chojniak MM
    Brachytherapy; 2013; 12(3):235-9. PubMed ID: 22436517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible effects of radiobiological parameters on metastatic spread of uveal melanomas treated with 106Ru plaques.
    Kleineidam M; Guthoff R
    Ger J Ophthalmol; 1994 Jan; 3(1):22-5; discussion 25-6. PubMed ID: 8142877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruthenium applicators in the treatment of choroidal melanomas.
    Van Hijfte R; Verbraeken H; De Laey JJ
    Bull Soc Belge Ophtalmol; 1987; 224():51-8. PubMed ID: 3509023
    [No Abstract]   [Full Text] [Related]  

  • 18. [Late marginal recurrence of a choroidal melanoma after initially effective brachytherapy].
    Chassang B; Daniel E; Bonnin N; Bacin F; Chiambaretta F
    J Fr Ophtalmol; 2015 Feb; 38(2):e15-8. PubMed ID: 25542441
    [No Abstract]   [Full Text] [Related]  

  • 19. (106)Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence.
    Barker CA; Francis JH; Cohen GN; Marr BP; Wolden SL; McCormick B; Abramson DH
    Brachytherapy; 2014; 13(6):584-90. PubMed ID: 24880583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term results of cobalt 60 curietherapy for uveal melanoma].
    Bacin F; Kwiatkowski F; Dalens H; Rozan R; Gagyi S; Donnarieix D; Bard JJ; Robert JL
    J Fr Ophtalmol; 1998 May; 21(5):333-44. PubMed ID: 9759427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.